DiaSys is pleased to announce an innovative test to detect antibodies against the novel coronavirus SARS-CoV-2. This liquid-stable and state-of-the-art SARS-CoV-2 UTAB FS assay will soon be added to their portfolio along with the dedicated calibrators and controls. It is a particle enhanced immunoturbidimetric, liquid-stable assay allowing a qualitative resp. semi-quantitative detection of total antibodies against SARS-CoV-2 in human serum and plasma. The assay targets antibodies directed against the receptor binding domain (RBD) of the viral spike protein since those antibodies block the interaction between the virus and the host cell receptor, thereby effectively prevent the infection of SARS‐CoV‐2.
As indicated in the suffix of the product name UTAB – Universal Total Antibody - the test can be run on almost all clinical chemistry analyzers. The assay is characterized by high specificity as well as sensitivity and shows no cross-reactivity to other coronaviruses, which share partial sequence homology with SARS-CoV-2.
Exhibitor Data Sheet